Soleus Capital Management,
$2.9B 13F equity value
115 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Soleus Capital Management, covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| KRYS | KRYSTAL BIOTECH INC | 939,254 | $349M | 12.0% |
| CELC | CELCUITY INC | 1,704,318 | $178M | 6.1% |
| TGTX | TG THERAPEUTICS INC | 2,927,895 | $161M | 5.5% |
| PODD | INSULET CORP | 1,049,000 | $160M | 5.5% |
| NVCR | NOVOCURE LTD | 9,913,401 | $150M | 5.2% |
| UTHR | UNITED THERAPEUTICS CORP DEL | 225,587 | $122M | 4.2% |
| INSP | INSPIRE MED SYS INC | 1,931,436 | $86M | 3.0% |
| RIGL | RIGEL PHARMACEUTICALS INC | 1,843,504 | $72M | 2.5% |
| ANIP | ANI PHARMACEUTICALS INC | 867,760 | $72M | 2.5% |
| BBNX | BETA BIONICS INC | 4,393,714 | $69M | 2.4% |
Track Soleus Capital Management,'s 13F portfolio: $2.9B in reported holdings, 115 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}